Performance of BRCA1/2 mutation prediction models in male breast cancer patients.

about

Performance of BRCA1/2 mutation prediction models in male breast cancer patients.

Item

http://www.wikidata.org/entity/Q38739022

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Performance of BRCA1/2 mutation prediction models in male breast cancer patients.

@en

type

Item

label

Performance of BRCA1/2 mutation prediction models in male breast cancer patients.

@en

prefLabel

Performance of BRCA1/2 mutation prediction models in male breast cancer patients.

@en

P1476

Performance of BRCA1/2 mutation prediction models in male breast cancer patients

@en

P2093

C H M van Deurzen

http://www.w3.org/2001/XMLSchema#string

C P Schroder

http://www.w3.org/2001/XMLSchema#string

E W Blom

http://www.w3.org/2001/XMLSchema#string

J C Oosterwijk

http://www.w3.org/2001/XMLSchema#string

J T Wijnen

http://www.w3.org/2001/XMLSchema#string

J W M Martens

http://www.w3.org/2001/XMLSchema#string

L A M Janssen

http://www.w3.org/2001/XMLSchema#string

M A Adank

http://www.w3.org/2001/XMLSchema#string

M G E M Ausems

http://www.w3.org/2001/XMLSchema#string

M P G Vreeswijk

http://www.w3.org/2001/XMLSchema#string

P2860

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies

Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.

Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.

Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention.

Selecting a BRCA risk assessment model for use in a familial cancer clinic.

Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.

Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review

A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.

P304

52-59

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CGE.13065

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mar Rodríguez-Girondo

Christi J van Asperen

S Moghadasi

P577

2017-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28589637

http://www.w3.org/2001/XMLSchema#string